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Abstract
Using a Burkitt lymphoma-like gene expression signature, we recently deﬁned a high-risk molecular high-grade (MHG)
group mainly within germinal centre B-cell like diffuse large B-cell lymphomas (GCB-DLBCL), which was enriched for
MYC/BCL2 double-hit (MYC/BCL2-DH). The genetic basis underlying MHG-DLBCL and their aggressive clinical
behaviour remain unknown. We investigated 697 cases of DLBCL, particularly those with MYC/BCL2-DH (n= 62) by
targeted sequencing and gene expression proﬁling. We showed that DLBCL with MYC/BCL2-DH, and those with BCL2
translocation, harbour the characteristic mutation signatures that are associated with follicular lymphoma and its high-grade
transformation. We identiﬁed frequent MYC hotspot mutations that affect the phosphorylation site (T58) and its adjacent
amino acids, which are important for MYC protein degradation. These MYC mutations were seen in a subset of cases with
MYC translocation, but predominantly in those of MHG. The mutations were more frequent in double-hit lymphomas with
IG as the MYC translocation partner, and were associated with higher MYC protein expression and poor patient survival.
DLBCL with MYC/BCL2-DH and those with BCL2 translocation alone are most likely derived from follicular lymphoma or
its precursor lesion, and acquisition of MYC pathogenic mutations may augment MYC function, resulting in aggressive
clinical behaviour.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most
common lymphoma in adults, accounting for around 75%
of aggressive lymphomas. The current standard treatment
for DLBCL is immunochemotherapy, typically R-CHOP
(rituximab plus cyclophosphamide, doxorubicin, vincristine
and prednisone), with 60% of patients living 10 years or
more [1]. Patients who fail R-CHOP treatment respond
poorly to currently available alternative therapies, and
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mortality is highest within the ﬁrst two years after diagnosis
[1]. The ability to risk-stratify patients with a low prob-
ability of cure following R-CHOP at diagnosis, and to enter
them into clinical trials investigating alternative therapies is
a signiﬁcant unmet clinical need. A number of biomarkers
have been investigated, but only MYC translocation and to a
lesser extent, cell of origin (COO), are used routinely or in a
clinical trial [1].
MYC translocation occurs in ~10% of DLBCL, and is
frequently (21–83%) accompanied by an additional BCL2
and/or BCL6 translocation, known as double-hit (DH) or
triple-hit (TH) [2–15]. MYC/BCL2-DH DLBCL are gen-
erally aggressive and respond poorly to currently available
therapies, with the majority of patients dying within two
years of diagnosis, although a minority of cases experience
a long term survival [15, 16]. The clinical outcomes for
MYC/BCL6-DH DLBCL are less clear owing to the small
number of cases investigated and their heterogeneous COO
[14, 17, 18]. Patients with a single MYC translocation
(MYC-SH) show variable clinical courses. A subset of these
cases has TP53 mutations and displays a worse survival,
similar to that of MYC/BCL2-DH [18, 19]. There remains a
need to clarify the prognostic stratiﬁcation of MYC
translocation-bearing DLBCL.
Based on COO classiﬁcation, DLBCL has been divided
into two broad subgroups: activated B-cell like (ABC) and
germinal centre B-cell like (GCB) subtypes, with the ABC-
DLBCL showing enhanced NF-κB activation and generally
a worse prognosis [20, 21]. Although the COO classiﬁca-
tion provides broad biologically distinct categories, there is
an apparent heterogeneity in clinical outcome within each
subtype. Further subclassiﬁcation of these broad molecular
subtypes has been investigated by several recent studies
based on clustered genetic changes and/or gene expression
signatures [22–26]. Among these recent advances, Sha et al.
and Ennishi et al. have deﬁned a clinically and biologically
distinct high-risk subgroup within GCB-DLBCL using,
respectively, a Burkitt lymphoma-like or MYC/BCL2-DH-
founded gene expression signature [25–27]. This subgroup,
termed molecular high-grade (MHG) in the study by Sha
et al., is enriched in cases with MYC/BCL2-DH, and more
importantly includes other poor prognosis cases without the
double-hit, which are not readily identiﬁed by other meth-
ods [25, 28].
Intriguingly, although MHG-DLBCL is enriched in
MYC/BCL2-DH, a proportion of cases with MYC/BCL2-DH
do not have the MHG gene expression signature and these
cases show no worse survival than that of conventional
GCB-DLBCL (non-MHG) [25]. To understand the genetic
basis underlying MHG-DLBCL and its aggressive clinical
behaviour, we used targeted sequencing to investigate 697
cases of DLBCL, particularly enriched for those with MYC/
BCL2-DH(TH) (n= 62).
Methods
Case selection and materials
Of the 697 DLBCL cases included, 400 were from the
REMoDL-B trial (28 MYC translocation positive) and 297
(97 MYC translocation positive) from a UK population-
based cohort [25, 28]. The vast majority of cases in the
population-based cohort were from the Haematological
Malignancy Research Network (HMRN) (www.hmrn.org),
which tracks all haematological malignancies across 14
hospitals diagnosed by a centralised fully-integrated hae-
matopathology laboratory [29]. Case selection in the present
study was biased towards those with a MYC translocation,
which, together with BCL2 and BCL6 translocations, was
determined at the time of diagnosis (HMRN) or retro-
spectively collected from pathology records or by per-
forming interphase ﬂuorescent in situ hybridisation (FISH)
on TMA (REMoDL-B) [18, 25]. Among the population-
based cohort, ﬁve cases had a previous history of follicular
lymphoma (FL), and a further 28 cases had a histological
evidence of concurrent FL. For the REMoDL-B trial,
patients with a previous history of low-grade lymphoma
were excluded.
Formalin-ﬁxed parafﬁn-embedded (FFPE) diagnostic
tissue biopsy was available in each case and local ethical
guidelines were followed for the use of these tissue mate-
rials for research with the approval of the ethics committees
of the involved institutions (05-Q1604–10, 04-Q1205–125,
10-H0504–79).
DNA extraction and quality assessment
Haematoxylin and eosin stained FFPE tissue slides were
reviewed and tumour rich areas (>40%) in consecutive
sections were isolated by crude macrodissection in each
specimen. DNA was extracted using the QIAamp DNA
Micro Kit (QIAGEN, Crawley, UK) and quantiﬁed using a
Qubit® Fluorometer (Life Technologies, UK). The quality
of DNA samples was assessed by PCR of variably sized
genomic fragments using a standardised protocol [30].
Targeted sequencing by HaloPlexHS enrichment
and Illumina HiSeq sequencing
This was essentially carried out as described previously
[31]. Brieﬂy, 100 ng genomic DNA was subjected to tar-
geted enrichment of 70 genes (Table S1), which are
recurrently mutated in aggressive B-cell lymphomas using
a customised HaloPlexHS probe library (Agilent Tech-
nologies). The HaloPlexHS probes incorporate molecular
barcodes, hence allowing removal of PCR errors during
data analysis. Library preparation was performed
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according to the manufacturer’s instructions for FFPE
tissue samples. The pooled libraries were sequenced on an
Illumina HiSeq4000 (2 × 150 bp end sequencing protocol)
or HiSeq2500 (Rapid Run Mode 2 × 150 bp end sequen-
cing protocol). As stipulated by our previous study, DNA
samples amenable for PCR of ≥400 bp genomic fragments
were investigated in a single replicate, while those
amenable for PCR of 300 bp were analysed in duplicates,
with reproducible variants being considered as a true
change [31].
Variant calling and annotation
Sequence data analysis and variants calling were performed
using a previously validated in-house protocol [31]. Brieﬂy,
SNV were called using UniﬁedGenotyper with no down-
sampling [32]. As this was unable to call SNVs at <8%
AAF reliably, MuTect2 was additionally employed for
detection of hotspot mutations at low AAF values. Indel
detection was separately carried out on the recalibrated bam
ﬁles using Pindel v0.2.5 [33], which allowed detection of
indels as low as 2% AAF. Variant calling ﬁles were con-
catenated to produce one library vcf each for the SNV and
Indel pipelines, and then ﬁltered using vcftools v0.1.15 and
bedtools v2.25 for read depth, quality score and known
PCR/sequence artefacts. Further ﬁltering was carried out to
remove variants in intronic regions outside essential spli-
cing sites, SNPs with a minor allele frequency ≥0.1%
(dbSNP database, 1000 Genomes Project, the ExAC exome
sequencing database) and synonymous changes. In addition,
missense variants predicted to be benign by at least seven
out of nine functional prediction tools (SIFT, Polyphen2
HDIV, Polyphen2 HVAR, LRT, MutationTaster, Mutatio-
nAssessor, FATHMM, SVM score and LR score) were
excluded. The resulting variants were further scrutinised by
reviewing the bam ﬁle to eliminate potential PCR and
sequence artefacts. Only variants above the cut-off value
(20 alternative allele depth for DNA samples amenable for
PCR of ≥400 bp, 15 alternative allele depth in both repli-
cates for DNA samples amenable for PCR of 300 bp) were
considered to be a true change [31]. Finally, extensive
search of COSMIC database and published literature was
carried out to retain those known and conﬁrmed to be
somatic variants. The ﬁnal mutation list can be found in
Table S2.
Molecular subtyping by gene expression proﬁling
Whole-genome gene expression proﬁling was performed on
mRNA extracted from FFPE diagnostic tissue specimens
using the Illumina whole-genome DASL array [34]. Data
analyses and COO classiﬁcation were carried out using the
“DLBCL automatic classiﬁer” (DAC) [35]. The MHG
group was identiﬁed based on a Burkitt lymphoma-like
signature as deﬁned in previous studies [25, 36].
Interphase ﬂuorescence in situ hybridisation (FISH)
Chromosome translocation status was available from rou-
tine haematopathological diagnosis or previous studies for
MYC, BCL2 and BCL6 in 550, 233 and 218 cases, respec-
tively [18, 25]. In the REMoDL-B and HMRN cohort, MYC
translocation was screened with Dako MYC break-apart
probe, and those showing no evidence of MYC translocation
but with MHG phenotype were further investigated with
Abbott MYC break-apart and MYC/IGH dual fusion probe.
In the remaining cases from other UK hospitals, MYC
translocation was investigated with Abbott MYC break-
apart probe.
Interphase FISH was performed for BCL2 and BCL6
translocation in 433 and 366 cases in the present study. In
cases with MYC translocation, additional FISH was per-
formed with MYC/IGH (Abbott) (if not yet done), then
MYC/IGK and MYC/IGL (Cytocell) dual fusion probes in
those without any evidence of MYC and IGH fusion. All
FISH was carried out on tissue microarray or whole tissue
section as described previously [18, 25].
MYC immunohistochemistry
Data on MYC protein expression by immunohistochemistry
on tissue microarrays (TMA) slides were available from our
previous study [25]. The immunostained slides were scan-
ned and MYC protein expression was quantiﬁed and pre-
sented as percentage of positive nuclear staining in
lymphoma cells using IHC Proﬁler Image-J software
according to the instructions for nuclear protein targets
(https://imagej.net/) [37].
Statistical analysis
The probability of MYC hotspot mutations occurring by
chance was assessed by Poisson regression. Associations
among chromosomal rearrangements, mutations and clinical
variables were analysed using Fisher’s exact test. Survival
analysis was carried out using Cox proportional hazards and
likelihood ratio tests in R (https://cran.r-project.org). All
quoted P values are two-sided.
Results
Among the 697 cases investigated by targeted sequencing,
553 were investigated for chromosomal translocations by
interphase FISH; and MYC, BCL2 and BCL6 translocations
were found in 125, 136 and 97 cases, respectively, with
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with. . .
MYC/BCL2/BCL6-TH in 11, MYC/BCL2-DH in 51 (BCL6
translocation data unknown in 8) and MYC/BCL6-DH in 22
(Figs. 1 and 2).
The mutation proﬁle of DLBCL with MYC/BCL2-DH or
BCL2-SH suggests their derivation from follicular
lymphoma
In general, DLBCL with MYC/BCL2/BCL6-TH and MYC/
BCL2-DH had a similar mutation proﬁle, and were char-
acterised by a higher mutation load and more frequent
mutations in BCL2, KMT2D, CREBBP, EZH2 and
TNFRSF14 than those with isolated MYC translocation
(Figs. 2a, S1 and S2). Interestingly, these mutations are the
cardinal features of FL [38–42], and were similarly seen in
DLBCL with BCL2-SH (Fig. 2b). The BCL2 mutation
proﬁle was almost identical between BCL2 translocation
positive DLBCL and FL (Fig. 2c) [42]. These ﬁndings
suggest that DLBCL with a BCL2 translocation may be
derived from a FL or its precursor lesion. In support of this
suggestion, DLBCL with MYC/BCL2-DH(TH) and those
with BCL2-SH also harboured an additional mutation pro-
ﬁle (MYC, GNA13, TP53, P2RY8, PIM1, CCND3, B2M,
EBF1 and S1PR2), which was associated with high-grade
transformation of FL as shown by several previous studies
(Fig. 2b) [38–41]. Furthermore, both groups (28 and 50%,
respectively) frequently presented with either a previous or
concurrent FL (Fig. 2d). Intriguingly, DLBCL with MYC-
BCL2-DH(TH) were more often associated with a previous,
but not concurrent FL than those with BCL2-SH. None-
theless, 65% of BCL2 translocation positive cases lacked
documented evidence of FL at diagnosis (Fig. 2d). With the
exception of MYC mutations, there was no signiﬁcant dif-
ference in the mutation proﬁle between BCL2 translocation
positive cases with and without FL (Fig. S3).MYC mutation
was more frequent in BCL2 translocation positive cases
without FL, and this was primarily due to a high frequency
of MYC translocation in this group.
As expected, DLBCLs with MYC/BCL2-DH(TH) were
either MHG (56%) or GCB (38%), the remaining cases
being unclassiﬁable (6%) (Fig. 3). Similarly, the majority of
DLBCL with BCL2-SH were GCB (74%), with the
remaining cases distributed among MHG (14%), ABC (4%)
and unclassiﬁed (8%). It is worth noting that the three cases
of ABC-DLBCL with BCL2-SH lacked both EZH2 and
GNA13 mutations that were nearly exclusively seen in GCB
(MHG)-DLBCL.
MHG-DLBCL with MYC translocation are enriched
with MYC mutations that enhance its stability and
transforming capacity
Our previous study showed that among patients with a MYC
translocation, MHG-DLBCL had a signiﬁcantly worse
survival than GCB-DLBCL (non-MHG) [25]. To under-
stand the genetic basis underlying MHG-DLBCL and its
aggressive clinical behaviour, we compared the mutation
proﬁle among MHG, GCB and ABC subtype, and also
between MHG and GCB within MYC/BCL2 double-hit
groups (Fig. 4). This revealed a signiﬁcantly higher fre-
quency of MYC mutations in the MHG group (Fig. 4b).
MYC is a known target of somatic hypermutation
machinery, and as expected many of the MYC mutations
were in the RCY-motif (R=A/G, Y= C/T), with their
extent attenuating when further downstream from the pro-
moter (Fig. 5a). In comparison with synonymous mutations,
there was a signiﬁcant enrichment of non-synonymous
changes in codons 57, 58 and 59 (Fig. 5a). In addition, an
in-frame deletion of codons 56–60 was seen in one case.
These mutations are likely to be functional, pathogenic and
selected during lymphoma development as they affect the
phosphorylation site (T58) and its neighbouring amino
acids, which are important for MYC protein degradation
[43]. Several lymphoma derived MYC mutants, including
P57S and T58A, have been previously shown to dramati-
cally increase the half-life of MYC protein, and also confer
increased transforming capacity [44, 45].
These MYC hotspot mutations were seen in a subset of
DLBCL with MYC translocation, more frequently in those
with MYC/BCL2-DH, and the majority (74%) were MHG
(Fig. 5b). In contrast, cases with MYC non-synonymous
mutations in other codons did not show any association
Populaon-based cohort (HMRN)        REMoDL-B clinical trial    Populaon-based cohort (other UK hospitals)
DATA available     DATA n/a
Fig. 1 Summary of cases of DLBCL included in the study. A total
of 697 cases were studied, including 400 from the REMoDL-B trial
and 297 cases from population-based cohort, mainly from the
Haematological Malignancy Research Network (HMRN). Laboratory
data on chromosome translocations and molecular subtypes by gene
expression proﬁling are indicated.
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with molecular subtype although occurred predominantly in
those with MYC/IG translocation (Fig. 5b, c). MYC hotspot
mutations were signiﬁcantly more frequent in cases with
MYC/IG (41%) than those with MYC/non-IG translocation
(8%), and together had a considerable overlap with MHG
phenotype (Fig. 5c). Cases withMYC hotspot mutations had
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a signiﬁcantly higher MYC protein expression than those
with other MYC mutations (Fig. 5d) as shown by immu-
nohistochemistry and quantitative analysis of the scanned
immunostained slides [25]. Finally, MYC pathogenic
mutations had a potential adverse effect on patient survival
(Fig. 6). Even within the MHG group, cases with MYC
pathogenic mutations had signiﬁcantly worse overall sur-
vival than those without these mutations in the REMoDL-B
trial, and a similar trend was also seen in HMRN’s
population-based cohort (Fig. 6a, b). In a separate analysis
within cases with MYC/BCL2-DH irrespective of their
MHG status, cases with MYC pathogenic mutations also
had signiﬁcantly worse overall survival than those without
these mutations in the REMoDL-B trial, albeit not in
HMRN’s population-based cohort (Fig. S4). In multi-
variable analysis adjusting for MHG and MYC/BCL2-DH,
MYC pathogenic mutations retained statistical signiﬁcance
in the REMoDL-B group, albeit not in the HMRN cohort.
A low allelic frequency (4–5% AAF) of the above MYC
pathogenic mutations was seen in three cases, likely
representing a subclonal change. Among these three cases,
two had molecular subtyping data and one was MHG.
DLBCL with MYC/BCL6-DH or BCL6-SH, or MYC-SH
are heterogeneous in their mutation proﬁle and
molecular subtype
There was no apparent mutation signature, nor biased
molecular subtype associated with BCL6 translocation with
exception of BCL10 and NOTCH2 mutations which were
signiﬁcantly enriched in cases with MYC/BCL6-DH or
BCL6-SH (Figs. 2a, 3 and S5). Similarly, there was no
speciﬁc mutation signature in DLBCL with MYC-SH with
the exception of high frequent MYC mutations. Cases with
MYC-SH varied in their molecular subtype, nonetheless
MHG (39%) and GCB (29%) accounted for the majority.
Interestingly, 6 of the 11 MHG-DLBCL with MYC-SH had
TP53 mutations.
Discussion
Using integrated analyses of chromosome translocation,
somatic mutation proﬁling of a panel of 70 genes that are
recurrently mutated in aggressive B-cell lymphoma, and
molecular subtype in a large cohort of DLBCL, the present
study made two novel observations.
First, we have provided several strands of evidence
indicating that DLBCL with MYC/BCL2-DH and those
with BCL2-SH are most likely derived from a low-grade
FL or its precursor lesion. These include ﬁnding: (1) a
cardinal mutation signature (BCL2, KMT2D, CREBBP,
EZH2 and TNFRSF14) associated with FL development;
(2) a mutation proﬁle (MYC, GNA13, TP53, P2RY8, PIM1,
CCND3, B2M, EBF1 and S1PR2) associated with FL
high-grade transformation; and (3) frequent presence
of a previous or concurrent FL in DLBCL with BCL2
translocation.
We acknowledge the limitation of the relatively small
gene panel used in the present study, and the above
Fig. 2 DLBCL with BCL2 translocation harbour the cardinal
mutation signature of follicular lymphoma. a Heatmap illustration
of mutation distribution according to chromosome translocation status;
Where data available, evidence of previous or concurrent follicular
lymphoma is indicated. b DLBCL with BCL2 translocation, particu-
larly those with MYC/BCL2-DH, harbour the cardinal mutation sig-
nature of FL, and also the mutation proﬁle associated with its
high-grade transformation [38–41]. Representative mutation data in FL
and transformed FL are from the study by Kridel et al. [41], with EZH2
mutation considered as the core changes associated with FL [38–41].
c Comparison of BCL2 mutation proﬁle between BCL2 translocation
positive DLBCL in the present study and FL in the study by Huet et al.
[42]. d DLBCL with BCL2 translocation often have a previous or
concurrent follicular lymphoma. MYC/BCL2-DH MYC/BCL2 double-
hit, TH MYC/BCL2/BCL6 triple-hit, SH single-hit, tr +ve/−ve trans-
location positive/negative, FL follicular lymphoma.
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14%
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Fig. 3 Molecular subtype of DLBCL according to translocation status. MHG molecular high-grade, GCB germinal centre B-cell like, ABC
activated B-cell like, UNC unclassiﬁed.
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speculation needs to be conﬁrmed by more comprehensive
genetic proﬁling. Nonetheless, the speculation is supported
by the ﬁnding that transformed FLs also show frequent
MYC hotspot mutation [41]. In support of our study, the
mutation signature associated with FL was also the char-
acteristic change in high-grade B-cell lymphoma with MYC
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was used to analyse the
difference of mutation frequency
between various groups with
statistical signiﬁcance indicated.
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with. . .
and BCL2 translocations [46], and in the EZB or C3 genetic
subgroup, which are enriched by BCL2 translocation
[23, 24].
Intriguingly, DLBCL with MYC/BCL2-DH had strong
mutation signatures associated with FL, but less frequent
evidence of a concurrent FL than those with BCL2-SH
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(28% vs 50%). Given the highly proliferative nature of
DLBCL with MYC/BCL2-DH, these high-grade lymphoma
cells may frequently efface the low-grade FL lesion,
potentially leading to its underdetection. In addition, a
single lymph node is commonly biopsied for histological
diagnosis, increasingly needle core rather than excision
biopsies. This would underestimate the true incidence of FL
in patients with DLBCL. Alternatively, DLBCL with MYC/
BCL2-DH may be derived from a precursor lesion, such as a
common mutated precursor cell population. In fact, trans-
formed FLs are more commonly (66–83%) derived from a
common mutated precursor cell (CPC) population, in a
process of divergent evolution [38–41]. The tissue com-
partment containing the CPC population is likely to be
in situ follicular neoplasia (ISFN), the precursor lesion of
FL, albeit this remains to be conﬁrmed in future investi-
gations. It is pertinent to speculate that BCL2 translocation
positive DLBCL could be similarly derived from an ISFN
lesion, regardless of any evidence for parallel FL
development.
Second, we have identiﬁed frequent MYC hotspot
mutations that affect the phosphorylation site (T58) and its
adjacent amino acids, which are critical for FBXW7
mediated proteasome degradation (Fig. 5a) [43]. Such
lymphoma derived MYC mutants (T58A, P57S) have been
shown to increase the half-life of MYC protein from 30 to
110 min, and also confer increased transforming capacity,
but are defective in promoting apoptosis due to failure to
activate BIM [44, 45, 47]. Thus, these hotspot mutations are
likely to be pathogenic and selected during lymphoma
development.
Although these MYC hotspot mutations were seen in a
subset of cases with MYC translocation, they were
predominantly in MHG. This may explain, at least in part,
the heterogeneous molecular subtype and clinical outcome
of DLBCL with MYC translocation, including those with
MYC/BCL2-DH. MYC hotspot mutations (pathogenic
changes) were signiﬁcantly more frequent in cases with
MYC/IG than those with MYC/non-IG translocation (41%
vs 8%, P= 0.005), potentially explaining in part why these
cases showed a worse prognosis than those with non-IG
gene as the MYC partner [48, 49]. Cases with MYC
pathogenic mutations were signiﬁcantly associated with
higher MYC protein expression as assessed by immuno-
histochemistry and quantitative imaging analysis. This
could potentially explain in part the variability (20–100%)
of MYC protein expression in tumour cells of MYC trans-
location positive DLBCL [50]. The above ﬁndings are also
consistent with the observation that the adverse prognosis of
the MYC/BCL2-DH group is primarily due to those with IG
as MYC translocation partner [48, 51].
It is worth noting that the above MYC hotspot mutations
were also seen at a subclonal level, albeit in only a few
cases. This ﬁnding raises an interesting question about
whether tumour cells carrying these mutations are more
resistant to therapies, and could thus be enriched in resistant
or relapsed disease. If this is the case, the clinical impact of
these MYC mutations may be under-estimated in the present
study, as the investigation was exclusively based on diag-
nostic tissue biopsies.
More recently, a second hotspot of tumour-associated
MYC mutations was identiﬁed in codons 243–249
through meta-analysis of mutation data from Burkitt
lymphoma [52]. These mutants (T244A, P245A) pheno-
copy the aforementioned mutations in their enhanced
MYC protein stability, transforming capacity, and also
defective BIM activation [52]. We did not observe any
hotspot mutations in this region, but this could be due to
the relatively small number of cases in the present study,
or different mutation spectra between Burkitt and
DLBCL. Mutation in codon 138 has also been suggested
to enhance MYC protein stability and thus regarded as
pathogenic change in DLBCL [53, 54]. Nonetheless,
mutation in codon 138 was frequently accompanied by
the change in codon 58, and its independent impact
remains uncertain due to a very limited number of mutant
cases identiﬁed [54].
In the 2017 WHO lymphoma classiﬁcation, MYC/BCL6-
DH DLBCL are included in the double-hit category,
without any distinction from those with MYC/BCL2/BCL6-
TH or MYC/BCL2-DH [55]. We show here that DLBCL
with MYC/BCL6-DH are signiﬁcantly different in their
mutation proﬁle and molecular subtype from those with
MYC/BCL2/BCL6-TH or MYC/BCL2-DH. This observa-
tion is further supported by a recent study albeit based on a
smaller cohort [46]. In fact, MYC/BCL6-DH DLBCL are
Fig. 5 MYC pathogenic mutations and their relationship to mole-
cular subtype and genetic changes in DLBCL. a Distribution of
MYC variants with hotspot mutations clustered at the phosphorylation
site (T58) and its neighbouring amino acids that are important forMYC
degradation. *One case shows an in-frame deletion of codons 56–60
and all other mutations are missense changes. The codons 57, 58 and
59 hotspot mutations and the in-frame deletion are likely pathogenic
and selected during lymphoma development. MYC variants are
annotated according to transcript ENST00000377970.6 in keeping
with the literature. b MYC hotspot mutations in codons 57, 58 and 59
are seen in a subset of cases with MYC translocation, more frequent in
those with MYC/BCL2-DH, but are signiﬁcantly enriched in MHG-
DLBCL. c MYC hotspot mutations are more commonly seen in MYC/
BCL2-DH DLBCL with IG gene as the MYC translocation partner,
with a considerable overlap with MHG phenotype. d DLBCL with
MYC mutation in codons 57–59 show a signiﬁcantly higher MYC
protein expression than those with MYC translocation, but lacking
these pathogenic mutations. The MYC protein expression was inves-
tigated by immunohistochemistry, quantiﬁed using IHC Proﬁler
Image-J software and presented as percentage of positive nuclear
staining in lymphoma cells. Unpaired t-test was used to compare the
two groups. MHG molecular high-grade, GCB germinal centre B-cell
like, ABC activated B-cell like UNC, unclassiﬁed.
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Fig. 6 Prognostic value of MYC codons 57–59 mutations in
DLBCL. a Differential impact on survival between MYC mutations in
codons 57–59, and others. b MHG-DLBCL with MYC mutations
in codons 57–59 show the worst overall survival in comparison with
GCB-DLBCL. c Single variable Cox proportional hazards regression
analysis of progression-free survival in GCB-DLBCL. *In multi-
variable analysis adjusting for MHG and MYC/BCL2-DH, MYC
pathogenic mutations in codons 57–59 retain statistical signiﬁcance in
the REMoDL-B cohort, albeit not in the HMRN cohort.
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highly heterogeneous in their molecular subtypes, indicat-
ing their diverse COO, notwithstanding the high prevalence
of NOTCH2 mutations [23, 24]. BCL6 translocation is
recurrently seen in both follicular and marginal zone lym-
phoma [56–59]. It would be interesting to explore whether
MYC/BCL6-DH DLBCL also result from high-grade
transformation of a low-grade lesion such as follicular or
marginal zone B-cell lymphoma or their precursor lesions,
and their heterogeneous molecular subtypes reﬂect their
inherent features from their derived low-grade lesion.
These heterogeneities, in addition to the small numbers of
cases available for each study, may explain the disparate
clinical outcomes reported for MYC/BCL6-DH DLBCL
[14, 17, 18]. In light of this, MYC/BCL6-DH DLBCL
should not be regarded as a single group, and their biology
and clinical management need to be explored in the context
of their respective molecular subtype, rather than within the
double-hit category.
In summary, DLBCL with MYC/BCL2-DH harbour the
characteristic mutation signatures that are associated with
FL development and its high-grade transformation, sug-
gesting their derivation from FL or its precursor lesion,
probably following acquisition of a MYC translocation. Our
study also identiﬁes the novel association of MHG-DLBCL
with MYC hotspot mutations that enhance its stability and
transforming capacity, and further highlight the pathogenic
role of these mutations and their clinical signiﬁcance,
beyond transcriptional deregulation as a result of
translocation.
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